Literature DB >> 12848110

The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison.

Alice B Gottlieb1, Umesh Chaudhari, Daniel G Baker, Michelle Perate, Lisa T Dooley.   

Abstract

The Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA) are commonly used, but fail to measure quality of life and the patient's perception of well-being. In response to these limitations, the National Psoriasis Foundation (NPF) Medical Advisory Board has developed the NPF Psoriasis Score (NPF-PS). This article evaluates the degree of concordance between NPF-PS, PASI, and PGA scores via an investigator-initiated, single-center, double-blind, placebo-controlled study of thirty-three patients with moderate to severe plaque psoriasis. Our results indicated that NPF-PS was strongly correlated with PASI and PGA in this study, while better reflecting patient perception. This is the first report of a double-blind placebo-controlled study demonstrating this concordance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848110

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  11 in total

Review 1.  Psoriasis assessment tools in clinical trials.

Authors:  S R Feldman; G G Krueger
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

2.  Leukocyte mitochondrial DNA copy number is a potential non-invasive biomarker for psoriasis.

Authors:  Materah Salem Alwehaidah; Suad AlFadhli; Ghada Al-Kafaji
Journal:  PLoS One       Date:  2022-06-29       Impact factor: 3.752

Review 3.  Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis.

Authors:  Wendy Myers; Mobolaji Opeola; Alice B Gottlieb
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

4.  Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial.

Authors:  Torello Lotti; Sergio Chimenti; Andreas Katsambas; Jean-Paul Ortonne; Louis Dubertret; Daiana Licu; Jan Simon
Journal:  Arch Drug Inf       Date:  2010-03

5.  Association of cytokine gene polymorphisms with psoriasis in cases from the nile delta of egypt.

Authors:  Ahmad A Settin; Hanaa A Hassan; Rizk A El-Baz; Tahia A Hassan
Journal:  Indian J Dermatol       Date:  2011-05       Impact factor: 1.494

6.  Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.

Authors:  Kim A Papp; Darryl Toth; Les Rosoph
Journal:  BMC Dermatol       Date:  2006-10-26

7.  Evaluation of efalizumab using safe psoriasis control.

Authors:  Kim A Papp; Eric Henninger
Journal:  BMC Dermatol       Date:  2006-09-19

8.  The association between smoking and the prevalence of metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years.

Authors:  Agnieszka B Owczarczyk-Saczonek; Roman Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2015-10-29       Impact factor: 1.837

9.  Pediatric psoriasis: an update.

Authors:  Nanette B Silverberg
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

Review 10.  Treating pediatric plaque psoriasis: challenges and solutions.

Authors:  Jayakar Thomas; Kumar Parimalam
Journal:  Pediatric Health Med Ther       Date:  2016-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.